EUVIMEDEUVIMED entdecken
Crossref

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy

Yuto Ono iD, Yuki Kohada, Shinsaku Tasaka, Shunsuke Miyamoto iD, Tetsutaro Hayashi, Yukiko Honda, Naoyuki Kitamura, Ryo Tasaka, Kohei Kobatake iD, Yohei Sekino iD, Hiroyuki Kitano iD, Keisuke Goto und 5 weitere

The Prostate · 2025

DOI: 10.1002/pros.70117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Yuto Ono und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The diagnostic reliability of magnetic resonance imaging (MRI)/transrectal ultrasound (TRUS) fusion‐targeted re‐biopsy for prostate cancer (PCa) remains limited. Therefore, additional predictive markers are needed to improve patient selection. This study aimed to identify factors predictive of clinically significant PCa (csPCa) to develop a risk stratification model. The role of systematic biopsies was also investigated.

Methods

We retrospectively analyzed 194 patients who underwent MRI/TRUS fusion‐targeted re‐biopsies between 2017 and 2024. Lesions were scored according to the Prostate Imaging Reporting and Data System (PI‐RADS) version 2.0 or 2.1. Univariate and multivariate logistic regression analyses were conducted to identify predictors of csPCa, defined as Gleason score ≥ 3 + 4. Detection rates for csPCa were compared between groups. The diagnostic contribution of systematic biopsies was assessed separately.

Results

Of the 194 patients, 82 (42.3%) were diagnosed with csPCa. Multivariate analysis identified prostate‐specific antigen density (PSAD) ≥ 0.20 (odds ratio (OR): 6.56) and PI‐RADS ≥ 4 (OR: 12.38) as independent predictors of csPCa. Based on the PI‐RADS category and PSAD, patients were stratified into high‐, intermediate‐, and low‐risk groups. These risk stratification factors led to the classification of 83 (42.8%) patients as high‐risk, 77 (39.7%) as intermediate‐risk, and 34 (17.5%) as low‐risk, with csPCa detection rates of 74.7% (62/83), 24.7% (19/77), and 2.9% (1/34), respectively. Of the 82 patients with csPCa, 21 were diagnosed exclusively via systematic biopsies.

Conclusions

Combining PSAD with PI‐RADS improved risk stratification for csPCa in men who underwent MRI/TRUS fusion re‐biopsies, while systematic biopsies added diagnostic value. These findings support individualized evidence‐based re‐biopsy strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenMagnetic Resonance ImagingProstateHumansMaleRetrospective StudiesMiddle AgedAgedImage-Guided BiopsyUltrasonography, InterventionalNeoplasm GradingUltrasound, High-Intensity Focused, Transrectal

Stichwörter der Autor:innen

image‐guided biopsyprostatic neoplasmssystematic biopsytransrectal ultrasound

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
  • Department of Urology, JA Hiroshima General Hospital, Hiroshima, Japan.
  • Department of Diagnostic Radiology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
  • Kasumi Clinic, Hiroshima, Japan.
  • Department of Pathology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.

ORCID-Profile: Yuto Ono, Shunsuke Miyamoto, Kohei Kobatake, Yohei Sekino, Hiroyuki Kitano, Nobuyuki Hinata

Zitieren

APA

Ono, Y., Kohada, Y., Tasaka, S., Miyamoto, S., Hayashi, T., Honda, Y., Kitamura, N., Tasaka, R., Kobatake, K., Sekino, Y., Kitano, H., Goto, K., Goriki, A., Hieda, K., Kato, M., Takeshima, Y., & Hinata, N. (2025). Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy. The Prostate. https://doi.org/10.1002/pros.70117

Vancouver

Ono Y, Kohada Y, Tasaka S, Miyamoto S, Hayashi T, Honda Y, et al. Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy. The Prostate. 2025. doi:10.1002/pros.70117

BibTeX
@article{Ono2025,
  author = {Ono, Yuto and Kohada, Yuki and Tasaka, Shinsaku and Miyamoto, Shunsuke and Hayashi, Tetsutaro and Honda, Yukiko and Kitamura, Naoyuki and Tasaka, Ryo and Kobatake, Kohei and Sekino, Yohei and Kitano, Hiroyuki and Goto, Keisuke and Goriki, Akihiro and Hieda, Keisuke and Kato, Masao and Takeshima, Yukio and Hinata, Nobuyuki},
  title = {Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.70117}
}
Kostenlos starten →